Illumina, Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Illumina, Inc. has filed its quarterly report (10-Q) for the period ending March 31, 2024, detailing financial performance and key balance sheet items.</b>

AI Summary

ILLUMINA, INC. (ILMN) filed a Quarterly Report (10-Q) with the SEC on May 3, 2024. Illumina, Inc. filed a 10-Q report for the period ending March 31, 2024. The filing covers the first quarter of fiscal year 2024. The report includes financial data for the periods ending March 31, 2024, and comparative periods. Key financial statement components such as common stock, additional paid-in capital, and retained earnings are detailed. The company's principal business address is 5200 Illumina Way, San Diego, CA 92122.

Why It Matters

For investors and stakeholders tracking ILLUMINA, INC., this filing contains several important signals. This 10-Q filing provides investors with the latest financial snapshot of Illumina, Inc., crucial for understanding its current operational and financial health. The detailed financial data allows for analysis of trends in revenue, equity, and other key metrics compared to previous periods.

Risk Assessment

Risk Level: low — ILLUMINA, INC. shows low risk based on this filing. The filing is a standard 10-Q report, which is routine for publicly traded companies and does not contain immediate red flags.

Analyst Insight

Monitor future filings for detailed revenue breakdowns by product and service segments to assess growth trends.

Key Numbers

• 2024-03-31 — Period End Date (Reporting period)
• 2024-05-03 — Filing Date (Date of submission)
• 3826 — Standard Industrial Classification (Industry code for Laboratory Analytical Instruments)

Key Players & Entities

• ILLUMINA, INC. (company) — Filer name
• ILMN (company) — Ticker symbol
• 2024-05-03 (date) — Filing date
• 2024-03-31 (date) — Period of report
• 5200 ILLUMINA WAY, SAN DIEGO, CA 92122 (address) — Business address

FAQ

Industry Context

Illumina operates in the biotechnology and life sciences industry, focusing on DNA sequencing and array-based solutions.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, requiring regular disclosure of financial information.

What Investors Should Do

1. Review the full 10-Q for detailed financial statements and management's discussion.
2. Compare Q1 2024 results with historical data to identify performance trends.
3. Note any disclosures regarding litigation, regulatory matters, or significant business developments.

Key Dates

• 2024-03-31: Quarterly Period End — End of the reporting period for the 10-Q filing.
• 2024-05-03: Filing Date — Date the 10-Q report was officially submitted to the SEC.

Year-Over-Year Comparison

This is the initial 10-Q filing for the fiscal year 2024, providing the first quarterly update of the year.

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value ILMN The Nasdaq Stock Market

Filing Documents

• ilmn-20240331.htm (10-Q) — 1502KB
• ex101kreevesseparationagre.htm (EX-10.1) — 35KB
• fy24q1ex311.htm (EX-31.1) — 15KB
• fy24q1ex312.htm (EX-31.2) — 14KB
• fy24q1ex321.htm (EX-32.1) — 7KB
• fy24q1ex322.htm (EX-32.2) — 7KB
• ilmn-20240331_g1.jpg (GRAPHIC) — 7KB
• 0001110803-24-000024.txt (&nbsp;) — 7068KB
• ilmn-20240331.xsd (EX-101.SCH) — 46KB
• ilmn-20240331_cal.xml (EX-101.CAL) — 61KB
• ilmn-20240331_def.xml (EX-101.DEF) — 271KB
• ilmn-20240331_lab.xml (EX-101.LAB) — 620KB
• ilmn-20240331_pre.xml (EX-101.PRE) — 435KB
• ilmn-20240331_htm.xml (XML) — 903KB

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 36 OTHER KEY INFORMATION

Controls and Procedures

Controls and Procedures 36

Legal Proceedings

Legal Proceedings 36

Risk Factors

Risk Factors 37 Share Repurchases and Sales 40 Adoptions, Modifications or Terminations of Trading Plans 40 Exhibits 41 Form 10-Q Cross-Reference Index 42 2 Table of Contents Consideration Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q contains, and our officers and representatives may from time to time make, "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "continue," "project," "estimate," "expect," "strategy," "future," "likely," "may," "potential," "predict," "should," "will," or similar words or phrases, or the negatives of these words, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward looking. Examples of forward-looking statements include, among others, statements we make regarding: our expectations as to our future financial performance, results of operations, or other operational results or metrics; the benefits that we expect will result from our business activities and certain transactions we have completed, or may complete, such as product introductions, increased revenue, decreased expenses, and avoided expenses and expenditures; our expectations of the effect on our financial condition of claims, litigation, contingent liabilities, and governmental investigations, proceedings, and regulations; our strategies or expectations for product development, market position, financial results, and reserves; our ability to successfully implement cost reduction plans in a timely manner and the possibility that costs associated with our cost reduction plans are greater than we anticipate; our expectations regarding the pending divestiture of GRAIL, LLC (f/k/a GRAIL, Inc.) (GRAIL); the transitional measures imposed by the European Commission in connection with our acquisitio

View Full Filing

View this 10-Q filing on SEC EDGAR